Cadonilimab plus chemotherapy . PD-1 inhibitor plus chemotherapy as first-line treatment for advanced gastric or gastroesophageal junction cancer with PD-L1 combined positive score <5: a propensity-matched, retrospective cohort study.
코호트
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
8 patients (30.
I · Intervention 중재 / 시술
first-line cadonilimab plus chemotherapy (cadonilimab group) or PD-1 inhibitor plus chemotherapy (PD-1 inhibitor group) were included
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Immune-related AEs occurred in 8 patients (30.8%) in the cadonilimab group and 6 patients (23.1%) in the PD-1 inhibitor group. [CONCLUSIONS] Compared to PD-1 inhibitor plus chemotherapy, cadonilimab plus chemotherapy significantly improved PFS and OS with a manageable safety profile in the first-line treatment of advanced G/GEJ cancer with PD-L1 CPS <5 in a real-world setting.
[BACKGROUND] Cadonilimab (AK104) is a first-in-class bispecific antibody targeting programmed cell death-1 (PD-1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4).
- p-value P=0.006
- p-value P=0.03
- 95% CI 0.23-0.80
- HR 0.49
- 추적기간 11.0 months
APA
Zhao D, Wu Z, et al. (2026). Cadonilimab plus chemotherapy . PD-1 inhibitor plus chemotherapy as first-line treatment for advanced gastric or gastroesophageal junction cancer with PD-L1 combined positive score <5: a propensity-matched, retrospective cohort study.. Journal of gastrointestinal oncology, 17(1), 5. https://doi.org/10.21037/jgo-2025-aw-866
MLA
Zhao D, et al.. "Cadonilimab plus chemotherapy . PD-1 inhibitor plus chemotherapy as first-line treatment for advanced gastric or gastroesophageal junction cancer with PD-L1 combined positive score <5: a propensity-matched, retrospective cohort study.." Journal of gastrointestinal oncology, vol. 17, no. 1, 2026, pp. 5.
PMID
41816572 ↗
Abstract 한글 요약
[BACKGROUND] Cadonilimab (AK104) is a first-in-class bispecific antibody targeting programmed cell death-1 (PD-1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). This study evaluated the effectiveness and safety of cadonilimab plus chemotherapy PD-1 inhibitor plus chemotherapy as first-line treatment for advanced gastric/gastroesophageal junction (G/GEJ) cancer with programmed cell death-ligand 1 (PD-L1) combined positive score (CPS) <5.
[METHODS] Between August 2022 and August 2024, patients with PD-L1 CPS <5 G/GEJ cancer who received first-line cadonilimab plus chemotherapy (cadonilimab group) or PD-1 inhibitor plus chemotherapy (PD-1 inhibitor group) were included. After propensity score matching (PSM), the objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety were analyzed.
[RESULTS] Fifty-two patients were analyzed after PSM (26 per group). At data cutoff (February 28, 2025), median follow-up was 11.0 months [95% confidence interval (CI): 8.3-15.3]. Compared with the PD-1 inhibitor group, cadonilimab group exhibited a numerically higher ORR (73.3% . 57.1%, P=0.45). In addition, the median PFS [9.3 . 5.8 months; hazard ratio (HR) =0.43; 95% CI: 0.23-0.80; P=0.006] and OS (14.3 . 10.3 months; HR =0.49; 95% CI: 0.26-0.93; P=0.03) were significantly longer in the cadonilimab group than in the PD-1 inhibitor group. The incidence of treatment-related adverse events (AEs) was comparable between the two groups, occurring in 92.3% of patients receiving cadonilimab plus chemotherapy and 100.0% of those receiving PD-1 inhibitor plus chemotherapy. Immune-related AEs occurred in 8 patients (30.8%) in the cadonilimab group and 6 patients (23.1%) in the PD-1 inhibitor group.
[CONCLUSIONS] Compared to PD-1 inhibitor plus chemotherapy, cadonilimab plus chemotherapy significantly improved PFS and OS with a manageable safety profile in the first-line treatment of advanced G/GEJ cancer with PD-L1 CPS <5 in a real-world setting.
[METHODS] Between August 2022 and August 2024, patients with PD-L1 CPS <5 G/GEJ cancer who received first-line cadonilimab plus chemotherapy (cadonilimab group) or PD-1 inhibitor plus chemotherapy (PD-1 inhibitor group) were included. After propensity score matching (PSM), the objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety were analyzed.
[RESULTS] Fifty-two patients were analyzed after PSM (26 per group). At data cutoff (February 28, 2025), median follow-up was 11.0 months [95% confidence interval (CI): 8.3-15.3]. Compared with the PD-1 inhibitor group, cadonilimab group exhibited a numerically higher ORR (73.3% . 57.1%, P=0.45). In addition, the median PFS [9.3 . 5.8 months; hazard ratio (HR) =0.43; 95% CI: 0.23-0.80; P=0.006] and OS (14.3 . 10.3 months; HR =0.49; 95% CI: 0.26-0.93; P=0.03) were significantly longer in the cadonilimab group than in the PD-1 inhibitor group. The incidence of treatment-related adverse events (AEs) was comparable between the two groups, occurring in 92.3% of patients receiving cadonilimab plus chemotherapy and 100.0% of those receiving PD-1 inhibitor plus chemotherapy. Immune-related AEs occurred in 8 patients (30.8%) in the cadonilimab group and 6 patients (23.1%) in the PD-1 inhibitor group.
[CONCLUSIONS] Compared to PD-1 inhibitor plus chemotherapy, cadonilimab plus chemotherapy significantly improved PFS and OS with a manageable safety profile in the first-line treatment of advanced G/GEJ cancer with PD-L1 CPS <5 in a real-world setting.
🏷️ 키워드 / MeSH
같은 제1저자의 인용 많은 논문 (5)
- Lactate derived from cancer-associated fibroblasts promotes alternative splicing and castration resistance in prostate cancer.
- Graphicalized vision-language modeling for comprehensive lung nodule analysis and risk stratification.
- Critical considerations for the use of deep learning models in clinical oncology prediction.
- MetaScreener: a robust dual-mode framework for directional prioritization of actionable signatures through multi-dataset and multi-approach integration.
- Photodynamic therapy remodels the prostate cancer microenvironment by suppressing cancer-associated fibroblast-mediated calcium signaling.